|

MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence

RECRUITINGSponsored by The First Affiliated Hospital of Zhengzhou University
Actively Recruiting
SponsorThe First Affiliated Hospital of Zhengzhou University
Started2017-01-01
Est. completion2027-01-01
Eligibility
Age1 Year – 95 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04217018

Summary

This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine algorithms that able to predict molecular pathology or subgroups of gliomas.

Eligibility

Age: 1 Year – 95 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients must have radiologically and histologically confirmed diagnosis of primary glioma
* Life expectancy of greater than 3 months
* Must receive tumor resection
* Signed informed consent

Exclusion Criteria:

* No gliomas
* No sufficient amount of tumor tissues for detection of molecular pathology
* Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic devices
* Patients who are pregnant or breast feeding
* Patients who are suffered from severe systematic malfunctions

Conditions2

CancerGlioma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.